Paolo Tarantino: Grateful to be part of the ESMO Open team
Paolo Tarantino shared a post by on LinkedIn:
“Grateful to be part of the ESMO Open team!”
Quoting
“ESMO Open has increased from 8.7 to 11.7 and gone up from 64/366 to 46/404 in the oncology category ranking. It has moved from the 82nd to the 88th percentile. Thanks to previous editorial board to our actual dream team of associate editors ESMO and ESMO Open.”
Source: Paolo Tarantino/LinkedIn and
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.
Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology. He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.